Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine augmentation plus cognitive behavioral therapy in chronic treatment-resistant depression
2024-512478-86-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in treatment-resistant depression (TRD) and major depressive disorder (MDD) comparing Ketamine + psychotherapy with Sodium chloride (placebo) + psychotherapy (2 arms). Primary endpoint: Change in depressive symptoms (MADRS). Planned start Apr 2024; status: authorised.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-512478-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512478-86-00.